Traditional clinical trials have long served as the cornerstone of medical research, providing essential evidence for evaluating the safety and efficacy of new interventions. However, these trials often encounter significant challenges, including inefficiencies, high costs, logistical complexities, and limited participant diversity. Post the COVID-19 pandemic era, a groundbreaking approach called decentralized clinical trials (DCTs) has emerged as the new normal, harnessing technological advancements to revolutionize the landscape of medical research. This article explores the principles, key